Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 179 results found. Search for [ Ranbaxy generic drugs ]

Results 1 to 21 of 179
E Kumar Sharma
New Delhi, December 31, 2019
Most in the Indian pharma industry are hopeful that the new National List of Essential Medicines (NLEM) expected in 2020 will not be too disruptive


PB Jayakumar
New Delhi, November 12, 2019
The divestment will curtail 13 per cent global revenues of Lupin, which had posted Rs 16,369 crore consolidated revenues for the financial year ended March 31, 2019


PB Jayakumar
New Delhi, November 8, 2019
Sun Pharma Q2 results: The drugmaker, which earns 37 per cent of its business from the US market, earned Rs 2,389.77 crore from the sale of formulations in the US in Q2FY20 against Rs 2397 crore in the corresponding quarter of the previous year


PB Jayakumar
New Delhi, July 22, 2019
Zydus Cadila, India's fourth-largest drug company by revenue, is banking big on research of new drugs, even though others have bowed out. Zydus expects the new drug business to grow to Rs 3,500 crore in four-five years


Sumant Banerji
New Delhi, July 22, 2019
Japanese firms have generally cracked the code of working in India's huge domestic market, but the extent of success varies


BusinessToday.In
New Delhi, April 11, 2019
The trouble is related to the implementation of the $500 million arbitration award that Singh brothers were ordered to pay to to Daiichi Sankyo in 2016. Besides, the siblings are caught in a financial mismanagement case in entities owned by them, including FHL and Religare Enterprises (REL).


PB Jayakumar
New Delhi, October 29, 2018
A big transformation is happening in the global generic pharmaceutical industry. As a result, stocks of most major drug companies have done badly in the past one year.


P.B. Jayakumar
New Delhi, April 30, 2018
Drug companies are moving up the value chain, transforming into complex generic manufacturers with high end R&D facilities.


Manoj K Singh
February 27, 2018
The enforcement of foreign arbitral awards in India has been a little difficult due to challenges like all convention countries not being notified by the government and thus unable to get their awards enforced in India and other such hindrances.


Gina Krishnan
New Delhi, February 6, 2018
With the Delhi High Court's verdict, Daiichi Sankyo has scored a victory against former Ranbaxy promoters. But it won't end there.


E Kumar Sharma
New Delhi, December 28, 2017
 The just concluded year, hurt Indian pharma companies in more ways than one


P.B. Jayakumar
New Delhi, December 11, 2017
Margin erosion and regulatory hurdles are hitting Indian pharma companies hard in their biggest market.


Rajeev Dubey
Delhi, May 1, 2017
A group of inheritors takes charge with new ideas and new strategies


Avneet Kaur
November 17, 2016
Out of BSE 500 companies, 291 companies-- excluding BFSI and Oil & Gas companies -- showed clear signs of improvement in bottom line in the second quarter of FY17. Net profit for this group showed a healthy growth of 9 per cent over the corresponding quarter last year. The y-o-y percentage growth in the same period last year was 2.61 per cent.


By E Kumar Sharma
Delhi, August 19, 2016
The fact that the $8-billion Fosun Group was keen on the US market makes the deal special, given that 62 per cent of Gland Pharma's revenues of $169 million in 2015 came from the US, compared to 16 per cent from India and the rest from other geographies.


E Kumar Sharma
July 6, 2016
Today, the research centre in Gurgaon remains the last remnant, in terms of a direct physical presence and arguably a positive highlight, of around $10-billion (986.4 billion yen) Japanese pharma major's misadventure in India.


Joe C Mathew
May 6, 2016
Breach of faith, dreams turned sour and a $5.35 billion hole in the pocket. That, in substance, was the Japanese pharma major Daiichi-Sankyo's failed India sojourn that began in June, 2008 and packed up in April, 2014.


Zeba Siddiqui
New Delhi, March 7, 2016
Dinesh Thakur, who exposed dangerous practices in generic drug industry in 2013, is accusing the drug regulators of failing to enforce safety rules in the $15 billion industry.


By Dinesh S. Thakur
Delhi, February 25, 2016
To realise its true potential and gain rapid in-market acceptance Indian pharma must have capable leaders with unimpeachable record to head its regulatory body.


P.B. Jayakumar and E. Kumar Sharma
Delhi, January 16, 2016
Since the past eight months the merged entity has been trading on the Bombay Stock Exchange, nervous investors have been asking two questions - is Shangvi's magic fading? Or, is the slump just a small hitch in Sun's glorious journey over the past one decade?


PAGES 1 OF 9  12345